Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia.

ABSTRACT:

Introduction

Cure rates for pediatric and young adult patients with refractory or recurrently relapsed acute lymphoblastic leukemia (ALL) are dismal. Survival from time of relapse is typically measured in weeks to months, and standard chemotherapy and currently approved targeted therapy achieve remission in less than a third of affected patients. To date, the only definitive curative therapy has been allogeneic hematopoietic stem cell transplant (HSCT). Advances in immunotherapy, with the introduction of chimeric antigen receptor T-cell therapies and the development of tisagenlecleucel, have changed the landscape. Areas covered: This review will describe the pharmacology of tisagenlecleucel and summarize the clinical evidence for its use in the treatment of multiple-relapsed or ref

SUBMITTER: Leahy AB 

PROVIDER: S-EPMC9237744 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature